Beijing Strong Biotechnologies,Inc. provides in-vitro diagnostics products and services in the People’s Republic of China and internationally. The company offers biochemistry reagents, including liver, renal, lipid, cardiac, diabetes, special protein, tumor marker, pancreas, inorganic, inflammation, TDM, and other panels; and coagulation products, such as prothrombin time, activated partial thromboplastin time, thrombin time, and fibrinogen, as well as antithrombin III, von Willebrand factor antigen, protein s activity, protein c, lupus anticoagulant, fibrin degradation products, and d-dimer. It also provides blood grouping card comprising ABO blood type anti stereotype detection card, DiaClon ABD-confirmation, and DiaClon ABO/D+ reverse grouping for patients; automatic coagulation analyzer, automatic biochemistry analyzer, and automated blood groupings analyzer; and SARS RBD neutralization antibody, SARS total antibody, SARS COV-2 antigen test kit for self testing, and SARS antigen card. In addition, the company provides technology and document services. It sells its products under the GCELL and Beijing MDC brands. The company was founded in 2001 and is headquartered in Beijing, the People’s Republic of China.
Metrics to compare | 300406 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300406PeersSector | |
---|---|---|---|---|
P/E Ratio | 18.6x | 21.4x | −0.5x | |
PEG Ratio | 3.41 | 0.21 | 0.00 | |
Price/Book | 2.5x | 2.0x | 2.6x | |
Price / LTM Sales | 5.6x | 6.2x | 3.0x | |
Upside (Analyst Target) | 37.4% | 24.5% | 53.8% | |
Fair Value Upside | Unlock | 21.9% | 9.6% | Unlock |